BR0313734A - Derivados do tiofeno, o seu processo de preparação e as composições farmacêuticas que os contêm - Google Patents

Derivados do tiofeno, o seu processo de preparação e as composições farmacêuticas que os contêm

Info

Publication number
BR0313734A
BR0313734A BR0313734-1A BR0313734A BR0313734A BR 0313734 A BR0313734 A BR 0313734A BR 0313734 A BR0313734 A BR 0313734A BR 0313734 A BR0313734 A BR 0313734A
Authority
BR
Brazil
Prior art keywords
sym
alkyl
halogen
pharmaceutical compositions
preparation process
Prior art date
Application number
BR0313734-1A
Other languages
English (en)
Inventor
Anne-Claude Dublanchet
Delphine Compere
Philippe Cluzeau
Stephane Blais
Alexis Denis
Pierre Ducrot
Karine Courte
Sophie Descamps
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR0313734A publication Critical patent/BR0313734A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"DERIVADOS DO TIOFENO, O SEU PROCESSO DE PREPARAçãO E AS COMPOSIçõES FARMACêUTICAS QUE OS CONTêM". A presente invenção refere-se a compostos com a fórmula (I) nos quais <sym> X represente oxigênio ou enxofre, <sym> Y represente oxigênio, -NH ou -N-alqUila(C~ 1~-C~ 6~), <sym> R~ 2~, represente hidrogênio, halogêneo, alquila (C~ 1~-C~ 3~), hidróxi, ou alcóxi(C~ 1~-C~ 3~), <sym> R~ b~ represente hidrogênio, halogêneo ou alquila(C~ 1~C~ 3~), <sym> A represente fenila, piridila, cicloalquila(C~ 5~-C~ 6~) ou cicloalquileno(C~ 5~-C~ 6~), <sym> R~ 1~ e R~ 2~ representem cada um deles um grupo selecionado dentre hidrogênio, halogêneo, ciano, halogenoalquila, halogenoalcóxi, alquila, alcenila, alcinila, -OR~ 4~, -NR~ 4~R~ 5~, -S(O)~ n~R~ 4~, -C(O)R~ 4~, -CO~ 2~R~ 4~, -C(O)NR~ 4~R~ 5~ -NR~ 5~-C(O)R~ 4~, -NR~ 5~-SO~ 2~NR~ 4~, -T-CN, -T-OR~ 4~, -T-OCF~ 3~, -T-NR~ 4~R~ 5~, -T-S(O)~ n~R~ 4~, -T-C(O)R~ 4~, -T-CO~ 2~R~ 4~, -T-O-C(O)R~ 4~, -T-C(O)NR~ 4~R~ 5~, -T-NR~ 4~C(O)R~ 5~, -T-NR~ 4~-SO~ 2~R~ 5~, -R~ 6~, e -T-R~ 6~, em que n, T, R~ 4~, R~ 5~ e R~ 6~ sejam tais como foram definidos na descrição, <sym> R~ 3~ represente um grupo -R~ 7~ ou -U-R~ 11~, nos quais R~ 7~ represente hidrogênio, alquila, arila, cicioalquila ou heterociclo., U represente uma cadeia alquileno linear ou ramificada, e R~ 11~, seja tal como foi definido na descrição, os seus isómeros ópticos ou os seus sais de adição de ácido ou de base aceitáveis do ponto de vista farmacêutico, e a sua utilização na qualidade de inibidores de metaloproteinase, e mais em particular da metaloproteinase-12.
BR0313734-1A 2002-08-13 2003-08-07 Derivados do tiofeno, o seu processo de preparação e as composições farmacêuticas que os contêm BR0313734A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02292037A EP1394159A1 (fr) 2002-08-13 2002-08-13 Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
PCT/EP2003/008750 WO2004018448A1 (fr) 2002-08-13 2003-08-07 Nouveaux derives de thiophene, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
BR0313734A true BR0313734A (pt) 2005-07-12

Family

ID=31197970

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0313734-1A BR0313734A (pt) 2002-08-13 2003-08-07 Derivados do tiofeno, o seu processo de preparação e as composições farmacêuticas que os contêm

Country Status (8)

Country Link
US (1) US20040072871A1 (pt)
EP (2) EP1394159A1 (pt)
JP (1) JP2006504674A (pt)
AU (1) AU2003251695A1 (pt)
BR (1) BR0313734A (pt)
CA (1) CA2497632A1 (pt)
MX (1) MXPA05001782A (pt)
WO (1) WO2004018448A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1493740A1 (fr) * 2003-07-03 2005-01-05 Warner-Lambert Company LLC Dérivés de 5-fluoro-thiophene, leur procédé de preparation, les compositions pharmaceutiques les contenant et leur utilisation comme inhibiteurs de métalloprotéinases
RU2391339C2 (ru) * 2004-08-19 2010-06-10 Квест Фармасьютикал Сёвисес (КьюПиЭс) 5-[3-(4-бензилоксифенилтио)-фур-2-ил]-имидазолидин-2,4-дион и аналоги в качестве ингибиторов эластазы макрофагов
JP2009522295A (ja) * 2005-12-30 2009-06-11 アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド 置換ビス−アミドメタロプロテアーゼ阻害剤
GB0713686D0 (en) * 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
JP5869222B2 (ja) 2008-01-04 2016-02-24 インテリカイン， エルエルシー 特定の化学的実体、組成物および方法
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US9090584B2 (en) * 2010-01-26 2015-07-28 Allergan, Inc. Therapeutic agents for treatment of ocular hypertension
CA2824197C (en) 2011-01-10 2020-02-25 Michael Martin Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
MA41253A (fr) * 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
MX2018016227A (es) 2016-06-24 2019-07-08 Infinity Pharmaceuticals Inc Terapias de combinacion.
ES2978192T3 (es) 2018-05-15 2024-09-06 Foresee Pharmaceuticals Usa Inc Inhibidores de metaloproteinasas de matriz (MMP) y métodos de uso de estos
TW202345793A (zh) * 2022-02-15 2023-12-01 南韓商治納輔醫藥科技有限公司 包含抑制前列腺素ｅ２受體之新穎化合物與抗癌藥物的用於治療癌症之藥學組成物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5425289A (en) * 1993-10-21 1995-06-20 Snap-On Incorporated Bung tool
DE3931432A1 (de) * 1989-09-21 1991-04-04 Hoechst Ag Pyrimidin-4,6-dicarbonsaeurediamide, verfahren zu deren herstellung sowie verwendung derselben sowie arzneimittel auf basis dieser verbindungen
US5260323A (en) * 1990-06-28 1993-11-09 Hoechst Aktiengesellschaft 2,4- and 2,5-substituted pyridine-N-oxides, processes for their preparation and their use
GB9424379D0 (en) * 1994-12-02 1995-01-18 Agrevo Uk Ltd Fungicides
US6080767A (en) * 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
CN1088711C (zh) * 1996-04-04 2002-08-07 盐野义制药株式会社 头孢烯化合物及含该化合物的医药
DE19629828A1 (de) * 1996-07-24 1998-01-29 Bayer Ag Carbanilide
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
US6013664A (en) * 1996-11-27 2000-01-11 Bayer Aktiengesellschaft Microbicidal agents based on thiophene-2-carboxylic acid derivatives
PT853083E (pt) * 1997-01-06 2001-12-28 Pfizer Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica
US6046229A (en) * 1998-01-06 2000-04-04 Industrial Technology Research Institute Polyaryl antitumor agents
CA2321025A1 (en) * 1998-02-09 1999-08-12 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines as protease inhibitors, in particular as urokinase inhibitors
EP1140768A1 (en) * 1998-12-30 2001-10-10 Bayer Aktiengesellschaft Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases
JP2002534435A (ja) * 1998-12-31 2002-10-15 アベンティス・ファーマスーティカルズ・インコーポレイテツド Ｍｍｐ−１２の選択的阻害剤
US6410013B1 (en) * 1999-01-25 2002-06-25 Musc Foundation For Research Development Viral vectors for use in monitoring HIV drug resistance
WO2000075129A1 (en) * 1999-06-07 2000-12-14 Shire Biochem Inc. Thiophene integrin inhibitors
MXPA03004926A (es) * 2001-02-14 2005-02-14 Warner Lambert Co Inhibidores de metaloproteinasas de matriz basados en pirimidinonas fusionadas.
DOP2002000333A (es) * 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
US6734207B2 (en) * 2001-04-20 2004-05-11 Parker Hughes Institute Cytotoxic compounds
US6924276B2 (en) * 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
EP1434585A1 (en) * 2001-10-12 2004-07-07 Warner-Lambert Company LLC Alkyne matrix metalloproteinase inhibitors
US6933298B2 (en) * 2001-12-08 2005-08-23 Aventis Pharma Deutschland Gmbh Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases
AU2002352443A1 (en) * 2001-12-21 2003-07-15 Consejo Superior De Investigaciones Cientificas Compounds and their therapeutic use related to the phosphorylating activity of the enzyme gsk-3
US6835745B2 (en) * 2002-01-15 2004-12-28 Wyeth Phenyl substituted thiophenes as estrogenic agents
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
JP2006501215A (ja) * 2002-08-13 2006-01-12 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としての単環式誘導体

Also Published As

Publication number Publication date
CA2497632A1 (fr) 2004-03-04
EP1394159A1 (fr) 2004-03-03
AU2003251695A1 (en) 2004-03-11
EP1534700A1 (fr) 2005-06-01
WO2004018448A1 (fr) 2004-03-04
US20040072871A1 (en) 2004-04-15
MXPA05001782A (es) 2005-04-25
JP2006504674A (ja) 2006-02-09

Similar Documents

Publication Publication Date Title
BR0313734A (pt) Derivados do tiofeno, o seu processo de preparação e as composições farmacêuticas que os contêm
BRPI0112986B8 (pt) compostos azabicíclicos, processo para a sua preparação, bem como composições farmacêuticas compreendendo os ditos compostos
BR0201697A (pt) Compostos de alfa-aminoácid0, processo para a sua preparação e composições farmacêuticas contendo os mesmos
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
BR0009641A (pt) Derivados de 1,4-benzotiazepin-1,1-dióxido, substituìdos com radicais de açúcar, processo para produção dos mesmos, medicamentos contendo esses compostos e sua utilização
CO4990929A1 (es) Compuestos de difenilurea sustituidos con sulfonamidas como antagonistas de los receptores de il-8
ECSP055815A (es) Composición para el tratamiento de la infección por virus flaviviridae
AR032436A1 (es) Oxazolidinonas substituidas, procedimiento para su preparacion, medicamentos, el uso de las mismas para la fabricacion de medicamentos, y el metodo para impedir la coagulacion sanguinea in vitro
BRPI0411721A (pt) derivados de tiazolilpiperidina como inibidores de mtp
BRPI0509368A (pt) antagonistas cgrp selecionados, processo para a sua fabricação bem como seu uso como medicamento
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
BR9802804A (pt) Compostos benzimidazol, benzoxazol e benzotiazol, processo para sua preparação e composições farmacéuticas contendo os mesmos.
BRPI0804091A2 (pt) compostos de 1,2,4,5-tetrahidro-3h-benzazepina, processo para sua preparação e composições farmacêuticas que os contêm
BR0210531A (pt) Derivados de ácido sulfÈnico
BR0308765A (pt) Compostos (4,2-dissubstituìdo-tiazol-5-il)amina como inibidores de pde7
BR0011282A (pt) Derivados da purina, seu processo de preparo e composiçoes farmacêuticas que as contêm
EA200600760A1 (ru) Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их
BR0104471A (pt) Compostos de ciclobutenodiona, um processo para a preparação dos mesmos e composições farmacêuticas que contêm os mesmos
BR0100234A (pt) Compostos de piperidina-4-sulfonamida, processo para a sua preparação e composições farmacêuticas contendo os mesmos
BRPI0501769A (pt) Compostos de pirrolidina e tiazolidina, processo para sua preparação e composições farmacêuticas contendo os mesmos
BR0016780A (pt) Derivados de piperazina substituìdos, preparação dos mesmos e seu uso como medicamentos
BR0214937A (pt) Processo de preparação de derivados de equinocandina
BRPI0510625A (pt) tienopiridinas como inibidores de ikk
BR0106248A (pt) Inibidores de metaloprotease, processo para a sua preparação e composições farmacêuticas contendo os mesmos
BR0308807A (pt) Compostos tiazol-2-il-imina como inibidores de pde-7

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired